May 22, 2020 - 9:00am

Add to My Calendar

Meeting Information:
Due to the COVID-19 pandemic, this meeting will be conducted online virtually using Microsoft Teams only. To access meeting, click here.

Registration required to attend. To register, click here.

  1. Call to order
  2. Approval of minutes from January 24, 2020 (vote required)
  3. Announcement: Drug Utilization Review Board Conflict of Interest Policy Review
  4. New business:

    Public comment on drug classes to be reviewed for the Medicaid (PDL):

    1. Anti-allergens, oral
    2. Antibiotics, inhaled
    3. Anticoagulants
    4. Antidepressants, other
    5. Antidepressants, selective serotonin reuptake inhibitors
    6. Antidepressants, tricyclic
    7. Antihyperuricemics
    8. Antiparkinsons agents
    9. Antivirals, oral/nasal
    10. Anxiolytics
    11. Beta blockers
    12. Bile salts
    13. Benign prostatic hyperplasia treatments
    14. Bronchodilators, beta agonist
    15. Chronic obstructive pulmonary disease agents
    16. Cough and cold agents
    17. Erythropoiesis stimulating proteins
    18. Glucagon agents
    19. Glucocorticoids, inhaled
    20. Hereditary angioedema treatments
    21. Immune globulins, intravenous
    22. Immunomodulators, asthma
    23. Lincosamides/oxazolidinones/streptogramins
    24. Lipotropics, other
    25. Lipotropics, statins
    26. Pulmonary arterial hypertension agents, oral and inhaled
    27. aa. Pancreatic enzymes
    28. bb. Pediatric vitamin preparations
    29. cc. Prenatal vitamins
    30. dd. Sedative hypnotics
    31. ee. Sickle cell anemia treatments
    32. ff. Thrombopoiesis stimulating proteins 
    33. gg. Urea cycle disorder, oral
  5. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid preferred drug list:
    1. Absorica LD (oral) / Acne agents, oral
    2. Reyvow (oral) / Antimigraine agents, other
    3. Ubrelvy (oral) / Antimigraine agents, other
    4. Secuado (transdermal) / Antipsychotics agents
    5. Gabacaine Kit (miscellaneous) / Neuropathic pain agents
    6. Ziextenzo syringe (subcutaneous) / Colony stimulating
  6. Therapeutic and Clinical Drug Reviews and Updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
  7. Executive work session

    Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.

  8. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
  9. Retrospective DUR:  Mariya Baranova, Pharm. D., MCMP-II, Conduent, LLC
    1. Report on recent retrospective DUR interventions:
      1. Prevention of adverse drug events in patients receiving opioids
      2. Pain management with opioids
      3. Monitoring of psychotropic drugs in youth
    2. Report on recent retrospective DUR intervention outcomes:
      1. Psychotropic drugs in adults
      2. Medication adherence
      3. Mental health disorder therapy management
      4. Respiratory disease management
    3. Retrospective DUR proposals (vote required)
      1. Asthma
      2. Nonsteroidal anti-inflammatory drugs (NSAIDS)
      3. Post-traumatic stress disorder (PTSD)
  10. Prospective prior authorization proposals (clinical edits):  Christina Faulkner, Pharm. D., BCPS, KEPRO, LLC (vote required)
    1. Monoclonal antibody agents for asthma - new criteria
    2. Ophthalmic immunomodulators - new criteria
    3. Transthyretin agents - new criteria
    4. Tricyclic antidepressants - new criteria
  11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program:  Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required)
    1. Benzodiazepines (not including sedative/hypnotics)
    2. Complement inhibitor and enzyme/protein replacement therapy
    3. Direct oral anticoagulants
    4. Hydroxy-methylglutaryl coenzyme A (HMG-COA) reductase inhibitors
    5. Low-molecular-weight heparins
    6. Nebulized bronchodilators
  12. Next meeting date: July 24, 2020
  13. Adjourn

Contact:  Questions regarding agenda items, content, or meeting arrangements should be directed to Maribel O Castoreno, DUR/Formulary Support Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-552-7672 or VDP-Advisory@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/meetings.

This meeting is open to the public.  Registration is required, as noted above, but there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Castoreno at 512-552-7672 at least 72 hours before the meeting so appropriate arrangements can be made.